Almost every GLP-1 drug you have heard of is a peptide, with all the injection-or-difficult-oral-delivery baggage that implies. US11851419B2 and US11702404B2 - both "GLP-1R modulating compounds," issued in 2023 to Gilead Sciences, Inc. - claim a different answer: small molecules.
The CPC class is the immediate tell. These grants sit in C07D 401/14 and related C07D heterocyclic-compound classes - the small-molecule chemistry buckets - not in C07K, the peptide-and-protein classes where semaglutide, tirzepatide, and their kin live. That single classification difference signals an entirely separate chemical lineage and prior-art pool.
Why does the chemistry distinction matter for scope and value? A small-molecule GLP-1R agonist can be a true oral tablet without the elaborate enteric formulations peptides require. The claims define specific heterocyclic scaffolds that modulate the receptor; the inventive limitation is the chemical structure, claimed as defined compounds or genera of compounds.
The claim-construction question is therefore a medicinal-chemistry one: which scaffolds, which substituents, what Markush breadth. A competitor's oral GLP-1R small molecule infringes only if its structure falls within the claimed chemical genus. This is composition-of-matter territory, where the claim's enforceable edge is the structural definition, not a method of use.
For the landscape, the small-molecule GLP-1R neighborhood is a strategically important white space relative to the peptide estate. It is chemically distinct, faces different prior art, and offers the oral-tablet prize that peptides struggle to match. A freedom-to-operate map for metabolic drugs has to treat C07D small-molecule GLP-1R claims as a separate field from the C07K peptide claims - they barely overlap.